Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should c

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.

A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting

Wall Street analysts reshuffled their bets on energy giants, homebuilders, and emerging space plays

Shares of United Therapeutics Corp. (NASDAQ:UTHR) are rising in Thursday morning trading following a

Shares of United Therapeutics are rising Thursday following a federal court victory in its patent li

United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The l

U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and oth

BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and a

As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order in

Liquidia Corp. shares gained 0.13% after hours after closing 57.19% lower following an adverse paten

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infri

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its dr

Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron ear

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

United Therapeutics is rated Buy, with a base case valuation of $535/share, despite recent revenue d

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

United Therapeutics NASDAQ: UTHR outlined plans to expand its pulmonary fibrosis, pulmonary hyperten

Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with

United Therapeutics Corporation (UTHR) Presents at Bernstein Insights: Healthcare Leaders and Disrup

United Therapeutics has declined ~12% since my last review, reducing its market cap to ~$21.1 billio

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporat

Corient Private Wealth LP reduced its holdings in United Therapeutics Corporation (NASDAQ: UTHR) by

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering

Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibroti

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvem

Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated pat

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and r

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra

The flights carried manufactured organs, being developed by United TherapeuticsThe flights are also

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in mil

United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics

United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopat

U.S. stock futures down on Monday. Focus on Baidu, Brady, United Therapeutics for earnings. XP and R

United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that th

Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of s

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and